Retatrutide: Research Applications

Research Applications

Retatrutide is used as a research tool in in vitro and preclinical (animal) studies of incretin and glucagon receptor pharmacology. Published laboratory research areas include:

1. Triple-Receptor Pharmacology — Characterization of simultaneous GIPR, GLP-1R and GCGR agonism, relative receptor potency (EC50) and downstream cAMP/PKA signaling in cell-based assays.[4]
2. Energy Balance in Rodent Models — In diet-induced obese (DIO) mice, Coskun et al. (2022) reported 36.9% body weight reduction (vs. 21.2% for tirzepatide) and 86.8% fat mass reduction, with engagement of all three receptors in vivo.[4]
3. Glucose Homeostasis — Preclinical study of glucose-dependent insulin secretion, β-cell signaling and the counterbalancing of glucagon receptor activity by GIP and GLP-1 receptor signaling.[4][11]
4. Hepatic Lipid Metabolism — Glucagon receptor–mediated effects on mitochondrial fatty acid oxidation and hepatic lipogenesis in animal models.[4][10]
5. Gastric Emptying — Urva et al. (2023) described a dose-dependent delay in gastric emptying in obese mice that attenuated with repeated exposure.[17]
6. Renal Research Models — Ma et al. (2025) compared retatrutide, liraglutide and tirzepatide in diabetic db/db mice, reporting reduced ALT, AST and lipid markers and mitigated inflammatory and fibrotic processes in kidney tissue.[15]
7. Tumor Biology Models — Marathe et al. (2025) reported reduced tumor engraftment, delayed tumor onset and attenuated tumor growth in pancreatic and lung cancer models in obese mice.[14]

Retatrutide is an investigational compound and is not approved by the FDA or EMA. Human clinical outcomes, doses and administration schedules are not summarized on this page.

For laboratory research use only. Not for human or veterinary use.